Page 1 - hypertension_newsletter7
P. 1
REFLECTIONS
Hypertension
Hypertension Global Newsletter #7 2024
TABLE OF CONTENTS
KEY ARTICLES Welcome back to the REFLECTIONS Hypertension
Global Newsletter series, which draws on the expertise of
GUIDELINES Hypertension
international physicians to summarise the latest clinical and
2024 ESC guidelines for the management of real-world evidence in the field of hypertension and reflect
elevated blood pressure and hypertension. on the clinical impact of these new data on the management
McEvoy JW, et al. Eur Heart J. 2024 Aug
30:ehae178. doi: 10.1093/eurheartj/ehae178. of patients with hypertension.
Online ahead of print.
Since our last newsletter, there have been very many new
The management of elevated blood pressure and interesting publications in the active field of clinical
in the acute care setting: A scientific statement research in hypertension, therefore the Scientific Planning
from the American Heart Association. Bress AP,
et al. Hypertension. 2024 Aug;81(8):e94-e106. Committee was tasked with choosing from an extensive
list of articles from high-quality scientific journals. To make
TARGETS AND TREATMENT this last selection, we privileged novel findings rather
Optimal antihypertensive systolic blood pressure: than confirmation papers, and articles directly applying to
A systematic review and meta-analysis. Whelton antihypertensive treatment in routine clinical practice. This
PK, et al. Hypertension. 2024 Sep 12. doi: 10.1161/ newsletter will focus on 1) recent clinical guidelines from the
HYPERTENSIONAHA.124.23597. Online ahead of
print. ESC and the AHA, 2) targets and treatments, and 3) special
populations – obesity. As with previous newsletters, we
Lowering systolic blood pressure to less than invite you to interact with this through links to commentary
120 mm Hg versus less than 140 mm Hg in
patients with high cardiovascular risk with and videos from authors of the publications, short video clinical
without diabetes or previous stroke: an open- perspectives from our SPC, and delve into the articles
label, blinded-outcome, randomised trial. Liu J, through hyperlinks for in-depth study.
et al. ESPRIT Collaborative Group. Lancet. 2024 Jul
20;404(10449):245-255. We are also pleased to share our Conference Corner,
Therapeutic inertia with initial low-dose where this time we highlight some abstracts of interest
quadruple combination therapy for hypertension: from the recent 2024 ESC Congress which took place in
Results from the QUARTET trial. Wang N, et al. London, England.
Hypertension. 2024 May;81(5):1087-1094.
Prof. Laurent (Chair)
Semaglutide and blood pressure: An individual
patient data meta-analysis. Kennedy C, et al.
Eur Heart J. 2024 Sep 1:ehae564. doi: 10.1093/ SCIENTIFIC PLANNING COMMITTEE
eurheartj/ehae564. Online ahead of print.
SPECIAL POPULATIONS Prof. Stéphane Laurent Prof. Diego Araiza
(France) (Mexico)
Medications for obesity: A review. Gudzune KA,
Kushner RF. JAMA. 2024 Aug 20;332(7):571-584.
ADDITIONAL ARTICLES OF INTEREST Prof. Adriana Camargo Dr. Om Narayan
(Brazil) (Australia)
CONFERENCE CORNER
HIGHLIGHTED ABSTRACTS OF INTEREST Prof. Nqoba Tsabedze Dr. Michal Fikrle
FROM THE ESC 2024 CONFERENCE (South Africa) (Czech Republic)
